ED
AMAG

Exane Derivatives’s AMAG Pharmaceuticals AMAG Stock Holding History

Exane Derivatives’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,206
Closed -$33.5K – 721
2018
Q4 		$33.5K Sell
2,206
-520
-19% -$9.91K 0.01% 404
2018
Q3 		$54.6K Buy
2,726
+370
+16% +$8.42K 0.01% 368
2018
Q2 		$47.5K Buy
2,356
+431
+22% +$9.54K 0.01% 391
2018
Q1 		$35.1K Sell
1,925
-1,124
-37% -$19K 0.01% 369
2017
Q4 		$40.4K Sell
3,049
-12,357
-80% -$186K 0.01% 359
2017
Q3 		$284K Sell
15,406
-5,601
-27% -$104K 0.05% 178
2017
Q2 		$386K Buy
21,007
+3,164
+18% +$62.7K 0.08% 154
2017
Q1 		$402K Sell
17,843
-1,549
-8% -$37.1K 0.09% 144
2016
Q4 		$675K Sell
19,392
-3,271
-14% -$97.7K 0.13% 131
2016
Q3 		$555K Buy
22,663
+3,000
+15% +$75K 0.08% 148
2016
Q2 		$470K Buy
19,663
+272
+1% +$6.24K 0.08% 132
2016
Q1 		$454K Buy
19,391
+5,613
+41% +$133K 0.06% 142
2015
Q4 		$416K Buy
+13,778
New +$445K 0.06% 128

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Exane Derivatives's AMAG Position: Q1 2019 in Review

Exane Derivatives sold out of AMAG Pharmaceuticals (AMAG) in Q1 2019, closing a stake of 2,206 shares — an estimated $33.5K sold.

Exane Derivatives first reported a position in AMAG in Q4 2015 and held it in 13 quarters. The position peaked at $675K in Q4 2016. 166 funds tracked by Wall St. Rank hold AMAG as of Q1 2019.

  • Exane Derivatives reported no remaining AMAG Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Exane Derivatives sold 2,206 AMAG Pharmaceuticals shares in Q1 2019, an estimated $33.5K.
  • Exane Derivatives first reported a position in AMAG Pharmaceuticals in Q4 2015 and held it in 13 quarters.
  • Exane Derivatives's AMAG Pharmaceuticals position peaked at $675K in Q4 2016.
  • 166 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2019.

Based on Exane Derivatives's 13F filing for Q1 2019, filed 24 Apr 2019.